Abstract
Background: The importance of examining the status of gastric inflammation has been acknowledged; the new classification by the updated Sydney system (USS) allows us to evaluate the quantitative status of gastric inflammation. However, this system is based on the histological classification derived from biopsy specimens. Therefore, more convenient, objective and practical biomarkers are recommended. Aim: We undertook a systematic review to find out potential biomarkers by summarizing the relationship between biomarkers and grades of inflammation. Methods: By a primary search via Medline up to December 2004, we extracted a total of 6,526 papers that described biomarkers for human gastric inflammation. All papers were screened by title and abstract. The authors then retrieved 435 citations for complete review; ultimately 231 were appropriate for inclusion criteria. These papers were subclassified into several categories and summarized by each author. Results: In addition to standard markers such as pepsinogens, we confirmed the close relationship between the levels of several biomarkers including gastrin, interleukin-8, HLA class II molecules, reactive oxygen species, and the histological grades. Conclusions: This review provides valuable information describing the clinical implication of these biomarkers for evaluating the static conditions or dynamic alterations of human gastric inflammation.
Journal Section:
Review
References
1.
Correa P: The biological model of gastric carcinogenesis. IARC Sci Publ 2004;157:301–310.
[PubMed]
2.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–789.
[PubMed]
3.
Dixon MF, Genta RM, Yardley JH, Correa P, participants in the International Workshop on the Histopathology of Gastritis, Houston 1994: Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996;20:1161–1181.
[PubMed]
4.
Samloff IM: Relationships among serum pepsinogen I, serum pepsinogen II and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology 1982;83:204–209.
[PubMed]
5.
Perasso A, Testino G, de Angelis P, Augeri C, de Grandi R: Gastric chief cell mass in chronic gastritis. Count and relationships to parietal cell mass and functional indices. Hepatogastroenterology 1991;38(suppl 1):63–66.
[PubMed]
6.
Yasunaga Y, Bonilla-Palacios JJ, Shinomura Y, Kanayama S, Miyazaki Y, Matsuzawa Y: High prevalence of serum immunoglobulin G antibody to Helicobacter pylori and raised serum gastrin and pepsinogen levels in enlarged fold gastritis. Can J Gastroenterol 1997;11:433–436.
[PubMed]
7.
Bodger K, Wyatt JI, Heatley RV: Variation in serum pepsinogens with severity and topography of Helicobacter pylori-associated chronic gastritis in dyspeptic patients referred for endoscopy. Helicobacter 2001;6:216–224.
8.
Inoue M, Kobayashi S, Matsuura A, Hamajima N, Tajima K, Tominaga S: Agreement of endoscopic findings and serum pepsinogen levels as an indicator of atrophic gastritis. Cancer Epidemiol Biomarkers Prev 1998;7:261–263.
[PubMed]
9.
Oksanen A, Sipponen P, Miettinen A, Sarna S, Rautelin H: Evaluation of blood tests to predict normal gastric mucosa. Scand J Gastroenterol 2000;35:791–795.
10.
Vaananen H, Vauhkonen M, Helske T, Kaariainen I, Rasmussen M, Tunturi-Hihnala H, Koskenpato J, Sotka M, Turunen M, Sandstrom R, Ristikankare M, Jussila A, Sipponen P: Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003;15:885–891.
11.
Kreuning J, Lindeman J, Biemond I, Lamers CB: Serological parameters in assessment of degree of gastritis in healthy volunteers. Dig Dis Sci 1995;40:609–614.
12.
Wagner S, Haruma K, Gladziwa U, Soudah B, Gebel M, Bleck J, Schmidt H, Manns M: Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication. Am J Gastroenterol 1994;89:1211–1218.
[PubMed]
13.
Sitas F, Smallwood R, Jewell D, Millard PR, Newell DG, Meuwissen SG, Moses S, Zwiers A, Forman D, Sitas F, Smallwood R, Jewell D: Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. Cancer Epidemiol Biomarkers Prev 1993;2:119–123.
[PubMed]
14.
Kiyohira K, Yoshihara M, Ito M, Haruma K, Tanaka S, Chayama K: Serum pepsinogen concentration as a marker of Helicobacter pylori infection and the histologic grade of gastritis: evaluation of gastric mucosa by serum pepsinogen levels. J Gastroenterol 2003;38:332–338.
15.
Haruma K, Mihara M, Okamoto E, Kusunoki H, Hananoki M, Tanaka S, Yoshihara M, Sumii K, Kajiyama G: Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-hour pH monitoring. Aliment Pharmacol Ther 1999;13:155–162.
16.
Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, Sumii M, Tanaka S, Yoshihara M, Chayama K: Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: A 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002;16:1449–1456.
17.
Ohkusa T, Takashimizu I, Fujiki K, Araki A, Honda K, Shimoi K, Sakurazawa T, Horiuchi T, Suzuki S, Ariake K, Ishii K: Changes in serum pepsinogen, gastrin, and immunoglobulin G antibody titers in Helicobacter pylori-positive gastric ulcer after eradication of infection. J Clin Gastroenterol 1997;25:317–322.
18.
Maconi G, Lazzaroni M, Sangaletti O, Bargiggia S, Vago L, Porro GB: Effect of Helicobacter pylori eradication on gastric histology, serum gastrin and pepsinogen I levels, and gastric emptying in patients with gastric ulcer. Am J Gastroenterol 1997;92:1844–1848.
[PubMed]
19.
Yasunaga Y, Shinomura Y, Kanayama S, Miyazaki Y, Bonilla Palacios JJ, Matsuzawa Y: Serum pepsinogen I levels and acid secretion in Helicobacter pylori associated enlarged fold gastritis. Ital J Gastroenterol 1996;28:457–461.
[PubMed]
20.
Park SM, Park J, Chang SK, Yoo BC, Kim HJ: Helicobacter pylori infection and serum pepsinogen I concentration in peptic ulcer patients: effect of bacterial eradication. Korean J Intern Med 1996;11:1–8.
[PubMed]
21.
Parente F, Imbesi V, Maconi G, Cucino C, Manzionna G, Vago L, Bianchi Porro G: Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study. Scand J Gastroenterol 1998;33:461–467.
22.
Chen TS, Tsay SH, Chang FY, Lee SD: Effect of eradication of Helicobacter pylori on serum pepsinogen I, gastrin, and insulin in duodenal ulcer patients: A 12-month follow-up study. Am J Gastroenterol 1994;89:1511–1514.
[PubMed]
23.
Hunter FM, Correa P, Fontham E, Ruiz B, Sobhan M, Samloff IM: Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis. Dig Dis Sci 1993;38:2081–2086.
24.
Fraser AG, Prewett EJ, Pounder RE, Samloff IM: Short report: Twenty-four-hour hyperpepsinogenaemia in Helicobacter pylori-positive subjects is abolished by eradication of the infection. Aliment Pharmacol Ther 1992;6:389–394.
[PubMed]
25.
Calam J: Helicobacter pylori, acid and gastrin. Eur J Gastroenterol Hepatol 1995;7:310–317.
[PubMed]
26.
Kaneko H, Konagaya T, Kusugami K: Helicobacter pylori and gut hormones. J Gastroenterol 2002;37:77–86.
27.
Tamm A, Villako K, Zilmer K: Distribution of serum gastrin in different forms of gastritis among Estonian population. Mater Med Pol 1990;22:124–7.
[PubMed]
28.
Calam J: Helicobacter pylori modulation of gastric acid. Yale J Biol Med 1999;72:195–202.
[PubMed]
29.
Turnipseed WD, Keith LM Jr: Altered serum gastrin levels in achlorhydric states. Am J Surg 1976;131:175–177.
30.
Sipponen P, Valle J, Varis K, Kekki M, Ihamaki T, Siurala M: Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa. An analysis of 860 subjects. Scand J Gastroenterol 1990;25:513–519.
[PubMed]
31.
Katelaris PH, Seow F, Lin BP, Napoli J, Ngu MC, Jones DB: Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. Gut 1993;34:1032–1037.
[PubMed]
32.
Haruma K, Kamada T, Kawaguchi H, Okamoto S, Yoshihara M, Sumii K, Inoue M, Kishimoto S, Kajiyama G, Miyoshi A: Effect of age and Helicobacter pylori infection on gastric acid secretion. J Gastroenterol Hepatol 2000;15:277–283.
33.
Marotta F, Hayakawa K, Mikami Y, Morello P, Sugai M, Morita T: Relationship between gastrin cell number, serum, antral mucosa and luminal gastrin concentration and gastric acidity in antral atrophic gastritis. Gut 1990;31:279–281.
[PubMed]
34.
Ohtaka Y, Azuma T, Konishi J, Ito S, Kuriyama M: Association between genetic polymorphism of the pepsinogen C gene and gastric body ulcer: the genetic predisposition is not associated with Helicobacter pylori infection. Gut 1997;41:469–474.
[PubMed]
35.
Laszewicz W, Zaremba-Woroniecka A, Gabryelewicz A: Helicobacter pylori infection and gastric secretion in duodenal and gastric ulcer patients – the effect of eradication after one year. J Physiol Pharmacol 1997;48:353–364.
[PubMed]
36.
Annibale B, Aprile MR, D’Ambra G, Caruana P, Bordi C, Delle Fave G: Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther 2000;14:625–634.
37.
Murayama Y, Miyagawa J, Shinomura Y, Kanayama S, Yasunaga Y, Nishibayashi H, Yamamori K, Higashimoto Y, Matsuzawa Y: Morphological and functional restoration of parietal cells in Helicobacter pylori associated enlarged fold gastritis after eradication. Gut 1999;45:653–661.
[PubMed]
38.
Tham TC, Chen L, Dennison N, Johnston CF, Collins JS, Ardill JE, Buchanan KD: Effect of Helicobacter pylori eradication on antral somatostatin cell density in humans. Eur J Gastroenterol Hepatol 1998;10:289–291.
[PubMed]
39.
Larkin CJ, Watson P, Sloan JM, Ardill JE, Patterson CC, McCluggage WG, Buchanan KD: Gastric corpus atrophy following eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2001;13:377–382.
40.
Furuta T, Baba S, Takashima M, Futami H, Arai H, Kajimura M, Hanai H, Kaneko E: Effect of Helicobacter pylori infection on gastric juice pH. Scand J Gastroenterol 1998;33:357–363.
41.
Witteman EM, Verhulst ML, de Koning RW, Hopman WP, Jansen JB: Basal serum gastrin concentrations before and after eradication of Helicobacter pylori infection measured by sequence specific radioimmunoassays. Aliment Pharmacol Ther 1994;8:515–519.
[PubMed]
42.
Verhulst ML, Hopman WP, Tangerman A, Jansen JB: Eradication of Helicobacter pylori infection in patients with non-ulcer dyspepsia. Effects on basal and bombesin-stimulated serum gastrin and gastric acid secretion. Scand J Gastroenterol 1995;30:968–973.
[PubMed]
43.
El-Omar E, Penman I, Dorrian CA, Ardill JE, McColl KE: Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 1993;34:1060–1065.
[PubMed]
44.
Park SM, Yoo BC, Lee HR, Yoon JH, Cha YJ: Antral Helicobacter pylori infection, hypergastrinemia and peptic ulcers: effect of eradicating the organism. Korean J Intern Med 1993;8:19–24.
[PubMed]
45.
Queiroz DM, Mendes EN, Rocha GA, Moura SB, Resende LM, Barbosa AJ, Coelho LG, Passos MC, Castro LP, Oliveira CA, et al: Effect of Helicobacter pylori eradication on antral gastrin- and somatostatin-immunoreactive cell density and gastrin and somatostatin concentrations. Scand J Gastroenterol 1993;28:858–864.
[PubMed]
46.
Graham DY, Go MF, Lew GM, Genta RM, Rehfeld JF: Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing. Scand J Gastroenterol 1993;28:690–694.
[PubMed]
47.
Queiroz DM, Mendes EN, Rocha GA, Moura SB, Resende LM, Cunha-Melo JR, Coelho LG, Passos MC, Oliveira CA, Lima Junior GF, et al: Histamine content of the oxyntic mucosa from duodenal ulcer patients: effect of Helicobacter pylori eradication. Am J Gastroenterol 1993;88:1228–1232.
[PubMed]
48.
Mulholland G, Ardill JE, Fillmore D, Chittajallu RS, Fullarton GM, McColl KE: Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17. Gut 1993;34:757–761.
[PubMed]
49.
Moss SF, Playford RJ, Ayesu K, Li SK, Calam J: pH-dependent secretion of gastrin in duodenal ulcer disease: effect of suppressing Helicobacter pylori. Digestion 1992;52:173–178.
[PubMed]
50.
Moss SF, Legon S, Bishop AE, Polak JM, Calam J: Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992;340:930–932.
51.
Karlsson FA, Burman P, Loof L, Mardh S: Major parietal cell antigen in autoimmune gastritis with pernicious anemia is the acid-producing H+,K+-adenosine triphosphatase of the stomach. J Clin Invest 1988;81:475–479.
[PubMed]
52.
Song YH, Ma JY, Mardh S, Liu T, Sjostrand SE, Rask L, Borch K, Huang GC, Barnett P, McGregor AM, Banga JP: Localization of a pernicious anaemia autoantibody epitope on the α-subunit of human H,K-adenosine triphosphatase. Scand J Gastroenterol 1994;29:122–127.
[PubMed]
53.
Ma JY, Borch K, Mardh S: Human gastric H,K-adenosine triphosphatase β-subunit is a major autoantigen in atrophic corpus gastritis. Expression of the recombinant human glycoprotein in insect cells. Scand J Gastroenterol 1994;29:790–794.
[PubMed]
54.
Claeys D, Faller G, Appelmelk BJ, Negrini R, Kirchner T: The gastric H+,K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology 1998;115:340–347.
[PubMed]
55.
Ito M, Haruma K, Kaya S, Kamada T, Kim S, Sasaki A, Sumii M, Tanaka S, Yoshihara M, Chayama K: Role of anti-parietal cell antibody in Helicobacter pylori-associated atrophic gastritis: Evaluation in a country of high prevalence of atrophic gastritis. Scand J Gastroenterol 2002;37:287–293.
56.
Betterle C, Mazzi PA, Pedini B, Accordi F, Cecchetto A, Presotto F: Complement-fixing gastric parietal cell autoantibodies. A good marker for the identification of type A chronic atrophic gastritis. Autoimmunity 1988;1:267–274.
[PubMed]
57.
Uibo R, Krohn K, Villako K, Tammur R, Tamm A: The relationship of parietal cell, gastrin cell, and thyroid autoantibodies to the state of the gastric mucosa in a population sample. Scand J Gastroenterol 1984;19:1075–80.
[PubMed]
58.
Mardh E, Mardh S, Mardh B, Borch K: Diagnosis of gastritis by means of a combination of serological analyses. Clin Chim Acta 2002;320:17–27.
[PubMed]
59.
Pfeiffer A, Kromer W, Friemann J, Ruge M, Herawi M, Schatzl M, Schwegler U, May B, Schatz H: Muscarinic receptors in gastric mucosa are increased in peptic ulcer disease. Gut 1995;36:813–818.
[PubMed]
60.
Ruoff HJ, Painz B, Becker M, Rack M, Sewing KF, Malchow H: Adenylate cyclase in human gastric mucosa: its activation by histamine in morphologically different biopsy specimens. Klin Wochenschr 1979;57:725–730.
61.
Hansen OH, Johansen A, Larsen JK, Pedersen T, Svendsen LB: Relationship between gastric acid secretion, histopathology, and cell proliferation kinetics in human gastric mucosa. Gastroenterology 1977;73:453–456.
[PubMed]
62.
Kaji T, Ishihara S, Ashizawa N, Hamamoto N, Endo H, Fukuda R, Adachi K, Watanabe M, Nakao M, Kinoshita Y: Adherence of Helicobacter pylori to gastric epithelial cells and mucosal inflammation. J Lab Clin Med 2002;139:244–250.
63.
Park J, Kim MK, Park SM: Influence of Helicobacter pylori colonization on histological grading of chronic gastritis in Korean patients with peptic ulcer. Korean J Intern Med 1995;10:125–129.
[PubMed]
64.
Scholte GH, van Doorn LJ, Cats A, Bloemena E, Lindeman J, Quint WG, Meuwissen SG, Kuipers EJ: Genotyping of Helicobacter pylori in paraffin-embedded gastric biopsy specimens: Relation to histological parameters and effects on therapy. Am J Gastroenterol 2002;97:1687–1695.
65.
Park SM, Kim JH, Hong YH, Jung HR, Park J, Kim JG, Yoo BC: Expression of mucosal cytochemokine mRNAs in patients with Helicobacter pylori infection. Korean J Intern Med 2001;16:230–235.
[PubMed]
66.
Harris PR, Weber HC, Wilcox CM, Jensen RT, Smith PD: Cytokine gene profile in gastric mucosa in Helicobacter pylori infection and Zollinger-Ellison syndrome. Am J Gastroenterol 2002;97:312–318.
67.
Shiotani A, Yamaoka Y, El-Zimaity Hala MT, Saeed MA, Qureshi Waqar A, Graham David Y: NSAID gastric ulceration: Predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite. Dig Dis Sci 2002;47:38–43.
68.
Ando T, Kusugami K, Ohsuga M, Ina K, Shinoda M, Konagaya T, Sakai T, Imada A, Kasuga N, Nada T, Ichiyama S, Blaser MJ: Differential normalization of mucosal interleukin-8 and interleukin-6 activity after Helicobacter pylori eradication. Infect Immun 1998;66:4742–4747.
[PubMed]
69.
Hamlet A, Lindholm C, Nilsson O, Olbe L: Aspirin-induced gastritis, like Helicobacter pylori-induced gastritis disinhibits acid secretion in humans: Relation to cytokine expression. Scand J Gastroenterol 1998;33:346–356.
70.
Yamamoto S, Kaneko H, Konagaya T, Mori S, Kotera H, Hayakawa T, Yamaguchi C, Uruma M, Kusugami K, Mitsuma T: Interactions among gastric somatostatin, interleukin-8 and mucosal inflammation in Helicobacter pylori-positive peptic ulcer patients. Helicobacter 2001;6:136–145.
71.
Russo F, Jirillo E, Clemente C, Messa C, Chiloiro M, Riezzo G, Amati L, Caradonna L, Di Leo A: Circulating cytokines and gastrin levels in asymptomatic subjects infected by Helicobacter pylori. Immunopharmacol Immunotoxicol 2001;23:13–24.
[PubMed]
72.
Rieder G, Einsiedl W, Hatz RA, Stolte M, Enders GA, Walz A: Comparison of CXC chemokines ENA-78 and interleukin-8 expression in Helicobacter pylori-associated gastritis. Infect Immun 2001;69:81–88.
73.
Isomoto H, Mizuta Y, Miyazaki M, Takeshima F, Omagari K, Murase K, Nishiyama T, Inoue K, Murata I, Kohno S: Implication of NF-κB in Helicobacter pylori-associated gastritis. Am J Gastroenterol 2000;95:2768–2776.
[PubMed]
74.
Martin Guerrero JM, Hergueta Delgado P, Esteban Carretero JJ, Rivera Hueto FF, Pellicer Bautista FJ, Herrerias Gutierrez JM: Pathogenic implications of interleukin-8 activity and bacterial phenotype in antral gastritis associated with Helicobacter pylori. Rev Esp Enferm Dig 2000;92:301–315.
[PubMed]
75.
Ohsuga M, Kusugami K, Ina K, Ando T, Yamaguchi H, Imada A, Nishio Y, Shimada M, Tsuzuki T, Noshiro M, Konagaya T, Kaneko H: Comparison between in vivo and in vitro chemokine production in Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:205–215.
76.
Sato Y, Sugimura K, Mochizuki T, Honma T, Suriki H, Tashiro K, Ishizuka K, Narisawa R, Ichida T, Van Thiel DH, Asakura H: Regional differences on production of chemokines in gastric mucosa between Helicobacter pylori-positive duodenal ulcer and gastric ulcer. Dig Dis Sci 1999;44:2390–2396.
77.
Bauditz J, Ortner M, Bierbaum M, Niedobitek G, Lochs H, Schreiber S: Production of IL-12 in gastritis relates to infection with Helicobacter pylori. Clin Exp Immunol 1999;117:316–323.
78.
Nielsen OH, Horn T, Prifti S, Peichl P, Scheibel JH, Lindley IJ: Gastric mucosal interleukin-8 and IL-8 antibody concentrations related to prevailing Helicobacter pylori infections. A Danish-Albanian study. Dan Med Bull 1999;46:249–252.
[PubMed]
79.
Zhang QB, Etolhi G, Dawodu JB, Gemmell CG, Russell RI: Relationship between mucosal levels of Helicobacter pylori-specific IgA, interleukin-8 and gastric inflammation. Clin Sci (Lond) 1999;96:409–414.
[PubMed]
80.
Shimoyama T, Everett SM, Dixon MF, Axon AT, Crabtree JE: Chemokine mRNA expression in gastric mucosa is associated with Helicobacter pylori cagA positivity and severity of gastritis. J Clin Pathol 1998;51:765–770.
[PubMed]
81.
Lindholm C, Quiding-Jarbrink M, Lonroth H, Hamlet A, Svennerholm AM: Local cytokine response in Helicobacter pylori-infected subjects. Infect Immun 1998;66:5964–5971.
[PubMed]
82.
Hahm KB, Lee KJ, Kim YS, Kim JH, Cho SW, Yim H, Joo HJ: Quantitative and qualitative usefulness of rebamipide in eradication regimen of Helicobacter pylori. Dig Dis Sci 1998;43:192S-197S.
83.
Yamaoka Y, Kita M, Kodama T, Sawai N, Tanahashi T, Kashima K, Imanishi J: Chemokines in the gastric mucosa in Helicobacter pylori infection. Gut 1998;42:609–617.
[PubMed]
84.
Suzuki H, Mori M, Sakaguchi AA, Suzuki M, Miura S, Ishii H: Enhanced levels of C-X-C chemokine, human GRO-α, in Helicobacter pylori-associated gastric disease. J Gastroenterol Hepatol 1998;13:516–520.
[PubMed]
85.
Sasayama Y, Kawano S, Tsuji S, Fusamoto H, Kamada T, Fukui H, Yoneda S, Okishio T: Relationship between interleukin-8 levels and myeloperoxidase activity in human gastric mucosa. J Gastroenterol Hepatol 1997;12:104–108.
[PubMed]
86.
Zhang QB, Dawodu JB, Husain A, Etolhi G, Gemmell CG, Russell RI: Association of antral mucosal levels of interleukin-8 and reactive oxygen radicals in patients infected with Helicobacter pylori. Clin Sci (Lond) 1997;92:69–73.
[PubMed]
87.
Taha AS, Curry GW, Morton R, Park RH, Beattie AD: Gastric mucosal hepatocyte growth factor in Helicobacter pylori gastritis and peptic ulcer disease. Am J Gastroenterol 1996;91:1407–1409.
[PubMed]
88.
Yamaoka Y, Kita M, Kodama T, Sawai N, Kashima K, Imanishi J: Expression of cytokine mRNA in gastric mucosa with Helicobacter pylori infection. Scand J Gastroenterol 1995;30:1153–1159.
[PubMed]
89.
Ando T, Kusugami K, Ohsuga M, Shinoda M, Sakakibara M, Saito H, Fukatsu A, Ichiyama S, Ohta M: Interleukin-8 activity correlates with histological severity in Helicobacter pylori-associated antral gastritis. Am J Gastroenterol 1996;91:1150–1156.
[PubMed]
90.
Fan XG, Chua A, Fan XJ, Keeling PW: Increased gastric production of interleukin-8 and tumour necrosis factor in patients with Helicobacter pylori infection. J Clin Pathol 1995;48:133–136.
[PubMed]
91.
Moss SF, Legon S, Davies J, Calam J: Cytokine gene expression in Helicobacter pylori associated antral gastritis. Gut 1994;35:1567–1570.
[PubMed]
92.
Noach LA, Bosma NB, Jansen J, Hoek FJ, van Deventer SJ, Tytgat GN: Mucosal tumor necrosis factor-α, interleukin-1β, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29:425–429.
[PubMed]
93.
Gionchetti P, Vaira D, Campieri M, Holton J, Menegatti M, Belluzzi A, Bertinelli E, Ferretti M, Brignola C, Miglioli M, et al: Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients. Am J Gastroenterol 1994;89:883–887.
[PubMed]
94.
Crabtree JE, Peichl P, Wyatt JI: Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 1993;37:65–70.
[PubMed]
95.
Sanduleanu S, Bruine AD, Biemond I, Stridsberg M, Jonkers D, Lundqvist G, Hameeteman W, Stockbrugger RW: Ratio between serum IL-8 and pepsinogen A/C: a marker for atrophic body gastritis. Eur J Clin Invest 2003;33:147–154.
96.
Holck S, Norgaard A, Bennedsen M, Permin H, Norn S, Andersen LP: Gastric mucosal cytokine responses in Helicobacter pylori-infected patients with gastritis and peptic ulcers. Association with inflammatory parameters and bacteria load. FEMS Immunol Med Microbiol 2003;36:175–180.
97.
Yasunaga Y, Shinomura Y, Kanayama S, Higashimoto Y, Yabu M, Miyazaki Y, Kondo S, Murayama Y, Nishibayashi H, Kitamura S, Matsuzawa Y: Increased production of interleukin-1β and hepatocyte growth factor may contribute to foveolar hyperplasia in enlarged fold gastritis. Gut 1996;39:787–794.
[PubMed]
98.
Basso D, Scrigner M, Toma A, Navaglia F, Di Mario F, Rugge M, Plebani M: Helicobacter pylori infection enhances mucosal interleukin-1β, interleukin-6, and the soluble receptor of interleukin-2. Int J Clin Lab Res 1996;26:207–210.
[PubMed]
99.
Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y: Effect of interleukin-1 polymorphisms on gastric mucosal interleukin-1β production in Helicobacter pylori infection. Gastroenterology 2002;123:1793–1803.
[PubMed]
100.
Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H: Interleukin-1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002;123:92–105.
101.
Thomson AB, Appleman S, Keelan M, Wallace JL: Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa. Dig Dis Sci 2003;48:308–314.
102.
Fan XJ, Chua A, O’Connell MA, Kelleher D, Keeling PW: Interferon-γ and tumour necrosis factor production in patients with Helicobacter pylori infection. Ir J Med Sci 1993;162:408–411.
[PubMed]
103.
Moss SF, Legon S, Davies J, Calam J: Cytokine gene expression in Helicobacter pylori associated antral gastritis. Gut 1994;35:1567–1570.
[PubMed]
104.
Taha AS, Kelly RW, Carr G, Carr G, Stiemer B, Morton R, Park RH, Beattie AD: Altered urinary interleukin-8/creatinine ratio in peptic ulcer disease: Pathological and diagnostic implications. Am J Gastroenterol 1996;91:2528–2531.
[PubMed]
105.
Kikuchi T, Kato K, Ohara S, Sekine H, Arikawa T, Suzuki T, Noguchi K, Saito M, Saito Y, Nagura H, Toyota T, Shimosegawa T: The relationship between persistent secretion of RANTES and residual infiltration of eosinophils and memory T lymphocytes after Helicobacter pylori eradication. J Pathol 2000;192:243–250.
106.
Agnihotri N, Bhasin DK, Vohra H, Ray P, Singh K, Ganguly NK: Characterization of lymphocytic subsets and cytokine production in gastric biopsy samples from Helicobacter pylori patients. Scand J Gastroenterol 1998;33:704–709.
107.
Karttunen R, Karttunen T, Ekre HP, MacDonald TT: Interferon-γ and interleukin-4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 1995;36:341–345.
[PubMed]
108.
Tomita T, Jackson AM, Hida N, Hayat M, Dixon MF, Shimoyama T, Axon AT, Robinson PA, Crabtree JE: Expression of Interleukin-18, a Th1 cytokine, in human gastric mucosa is increased in Helicobacter pylori infection. J Infect Dis 2001;183:620–627.
109.
Karhukorpi J, Yan Y, Niemela S, Valtonen J, Koistinen P, Joensuu T, Saikku P, Karttunen: Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin Exp Immunol 2002;128:326–332.
110.
Van Den Brink GR, ten Kate FJ, Ponsioen CY, Rive MM, Tytgat GN, van Deventer SJ, Peppelenbosch MP: Expression and activation of NF-κB in the antrum of the human stomach. J Immunol 2000;164:3353–3359.
[PubMed]
111.
Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002;25;295:683–686.
112.
Hatakeyama M: Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004;4:688–694.
113.
Roe I, Nam S, Kim J, Shin J, Bang W, Yang M: Association of the myeloperoxidase –463G→A polymorphism with development of atrophy in Helicobacter pylori-infected gastritis. Am J Gastroenterol 2002;97:1629–1634.
[PubMed]
114.
Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohara T, Kangawa K, Ishii H, Hibi T: Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio: a possible novel and non-invasive marker for gastric atrophy. Hepatogastroenterology 2004;51:1249–54,
[PubMed]
115.
Moss SF, Valle J, Abdalla AM: Gastric cellular turnover and the development of atrophy after 31 years of follow-up: A case-control study. Am J Gastroenterol 1999;94:2109–2114.
116.
Hoshi T, Sasano H, Kato K, Ohara S, Shimosegawa T, Toyota T, Nagura H: Cell damage and proliferation in human gastric mucosa infected by Helicobacter pylori – a comparison before and after H. pylori eradication in non-atrophic gastritis. Hum Pathol 1999;30:1412–1417.
117.
Isomoto H, Furusu H, Shin M, Ohnita K, Miyazaki M, Omagari K, Mizuta Y, Murase K, Inoue K, Murata I, Koji T, Kohno S: Enhanced expression of transcription factor E2F in Helicobacter pylori-infected gastric mucosa. Helicobacter 2002;7:152–162.
118.
Sougioultzis S, Foukas PG, Tzivras M, Kourtessas D, Gorgoulis VG, Davaris P, Archimandritis AJ: Alterations in the proliferating compartment of gastric mucosa during Helicobacter pylori infection: the putative role of epithelial cells expressing p27(kip1). Mod Pathol 2003;16:1076–1085.
119.
Shimada M, Ina K, Kyokane K, Imada A, Yamaguchi H, Nishio Y, Hayakawa M, Cinema Y, Ohta M, Ando T, Kusugami K: Upregulation of mucosal soluble fas ligand and interferon-γ may be involved in ulcerogenesis in patients with Helicobacter pylori-positive gastric ulcer. Scand J Gastroenterol 2002;37:501–511.
120.
Hasumi K, Tanaka K, Saitoh S, Takagi A, Miwa T, Mine T, Koga Y: Roles of tumor necrosis factor-α-receptor type 1 and Fas in the Helicobacter pylori-induced apoptosis of gastric epithelial cells. J Gastroenterol Hepatol 2002;17:651–658.
121.
Jankowski J, al-Rawi HJ, Johnston DA, Hopwood D, Filipe MI, Coghill G, Wormsley KG: Growth regulatory peptides in gastric mucosa. Clin Sci (Lond) 1992;82:581–587.
[PubMed]
122.
Hsu PI, Lai KH, Chien EJ, Lin CK, Lo GH, Jou HS, Cheng JS, Chan HH, Hsu JH, Ger LP, Hsu PN, Tseng HH: Impact of bacterial eradication on the cell proliferation and p53 protein accumulation in Helicobacter pylori-associated gastritis. Anticancer Res 2000;20:1221–1228.
[PubMed]
123.
Tari A, Kodama K, Sumii M, Tani H, Sumii K, Chayama K: Does intragastric nitrite concentration reflect gastric carcinogenesis in Japanese Helicobacter pylori-infected patients? Dig Dis Sci 2003;48:1730–1736.
124.
Akimoto M, Hashimoto H, Shigemoto M, Yamashita K, Yokoyama I: Changes of nitric oxide and growth factors during gastric ulcer healing. J Cardiovasc Pharmacol 2000;36:S282–S285.
125.
Konturek PC, Konturek SJ, Bobrzynski A, Kwiecien N, Obtulowicz W, Stachura J, Hahn EG, Rembiarz K: Helicobacter pylori and impaired gastric secretory functions associated with duodenal ulcer and atrophic gastritis. J Physiol Pharmacol 1997;48:365–373.
[PubMed]
126.
Marcinkiewicz M, Van Der Linden B, Peura DA, Goldin G, Parolisi S, Sarosiek J: Impact of Helicobacter pylori colonization on immunoreactive epidermal growth factor and transforming growth factor-α in gastric juice. Its potential pathogenetic implications. Dig Dis Sci 1996;41:2150–2155.
127.
Taha AS, Beastall G, Morton R, Park RH, Beattie AD: Insulin-like growth factor-1 in Helicobacter pylori gastritis and response to eradication using bismuth-based triple therapy. J Clin Pathol 1996;49:676–678.
[PubMed]
128.
Kondo S, Shinomura Y, Kanayama S, Higashimoto Y, Kiyohara T, Yasunaga Y, Kitamura S, Ueyama H, Imamura I, Fukui H, et al. Helicobacter pylori increases gene expression of hepatocyte growth factor in human gastric mucosa. Biochem Biophys Res Commun 1995;210:960–965.
129.
Akimoto M, Hashimoto H, Shigemoto M, Yamashita K, Yokoyama I: Changes of nitric oxide and growth factors during gastric ulcer healing. J Cardiovasc Pharmacol 2000;36:S282–285.
130.
Vestergaard EM, Poulsen SS, Gronbaek H, Larsen R, Nielsen AM, Ejskjaer K, Clausen JT, Thim L, Nexo E: Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 2002;48:1689–1695.
[PubMed]
131.
Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ: Cyclooxygenase-1 and -2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000;47:762–770.
132.
Konturek SJ, Konturek PC, Plonka A, Duda A, Sito E, Zuchowicz M, Hahn EG: Implication of gastrin in cyclooxygenase-2 expression in Helicobacter pylori infected gastric ulceration. Prostaglandins Other Lipid Med 2001;66:39–51.
133.
Weiler H, Weiler C, Gerok W: Gastric mucosal PGE2 levels in gastric non-ulcer and ulcer patients with chronic renal failure or without renal diseases and in healthy subjects. Dig Dis Sci 1990;35:1488–1493.
134.
Hudson N, Balsitis M, Filipowicz F, Hawkey CJ: Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:748–751.
[PubMed]
135.
Bode C, Maute G, Bode JC: Prostaglandin E2 and prostaglandin F2α biosynthesis in human gastric mucosa: effect of chronic alcohol misuse. Gut 1996;39:348–352.
[PubMed]
136.
Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, Meltzer SJ, Wilson KT: Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999;116:1319–1329.
[PubMed]
137.
Tatsuguchi A, Sakamoto C, Wada K, Akamatsu T, Tsukui T, Miyake K, Futagami S, Kishida T, Fukuda Y, Yamanaka N, Kobayashi M: Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori-related gastritis and gastric ulcer tissues in humans. Gut 2000;46:782–789.
138.
Ahmed A, Holton J, Vaira D, Smith SK, Hoult JR: Eicosanoid synthesis and Helicobacter pylori-associated gastritis: increase in leukotriene C4 generation associated with H. pylori colonization. Prostaglandins 1992;44:75–86.
139.
Hudson N, Balsitis M, Everitt S, Hawkey CJ: Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:742–747.
[PubMed]
140.
Ihan A, Krizman I, Ferlan-Marolt V, Tepez B, Gubina M: HLA-DR expression on CD8 lymphocytes from gastric mucosa in urease-positive and urease-negative gastritis. FEMS Immunol Med Microbiol 1995;10:295–299.
141.
Papadimitriou CS, Ioachim-Velogianni EE, Tsianos EB, Moutsopoulos HM: Epithelial HLA-DR expression and lymphocyte subsets in gastric mucosa in type B chronic gastritis. Virchows Arch A Pathol Anat Histol 1988;413:197–204.
142.
Valnes K, Huitfeldt HS, Brandtzaeg P: Relation between T cell number and epithelial HLA class II expression quantified by image analysis in normal and inflamed human gastric mucosa. Gut 1990;31:647–652.
[PubMed]
143.
Ishii N, Chiba M, Iizuka M, Watanabe H, Ishioka T, Masamune O: Expression of MHC class II antigens (HLA-DR, -DP, and -DQ) on human gastric epithelium. Gastroenterol Jpn 1992;27:23–28.
[PubMed]
144.
Seifarth C, Funk A, Reich K, Dahne I, Classen M, Deusch K: Selective increase of CD4+ and CD25+ T cells but not of γ δ T cells in H. pylori-associated gastritis. Adv Exp Med Biol 1995;4:931–934.
[PubMed]
145.
Chiba M, Ishii N, Ishioka T, Murata M, Masamune O, Sugiyama T, Yachi A: Topographic study of Helicobacter pylori and HLA-DR antigen expression on gastric epithelium. J Gastroenterol 1995;30:149–155.
[PubMed]
146.
Archimandritis A, Sougioultzis S, Foukas PG, Tzivras M, Davaris P, Moutsopoulos HM: Expression of HLA-DR, costimulatory molecules B7-1, B7-2, intercellular adhesion molecule-1 (ICAM-1) and Fas ligand (FasL) on gastric epithelial cells in Helicobacter pylori gastritis: influence of H. pylori eradication. Clin Exp Immunol 2000;119:464–471.
147.
Ohara T, Arakawa T, Higuchi K, Kaneda K: Overexpression of co-stimulatory molecules in peripheral mononuclear cells of Helicobacter pylori-positive peptic ulcer patients: Possible difference in host responsiveness compared with non-ulcer patients. Eur J Gastroenterol Hepatol 2001;13:11–18.
148.
Hatz RA, Meimarakis G, Bayerdorffer E, Stolte M, Kirchner T, Enders G: Characterization of lymphocytic infiltrates in Helicobacter pylori-associated gastritis. Scand J Gastroenterol 1996;31:222–228.
[PubMed]
149.
Fan X, Long A, Keeling PW, Kelleher D: Adhesion molecule expression on gastric intra-epithelial lymphocytes of patients with Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995;7:541–546.
[PubMed]
150.
Valnes K, Brandtzaeg P, Elgjo K, Stave R: Quantitative distribution of immunoglobulin-producing cells in gastric mucosa: relation to chronic gastritis and glandular atrophy. Gut 1986;27:505–514.
[PubMed]
151.
Faller G, Ruff S, Reiche N, Hochberger J, Hahn EG, Kirchner T: Mucosal production of antigastric autoantibodies in Helicobacter pylori gastritis. Helicobacter 2000;5:129–134.
152.
Karttunen TJ, Niemela S, Kerola T: Blood leukocyte differential in Helicobacter pylori infection. Dig Dis Sci 1996;41:1332–1336.
153.
Yamamoto I, Fukuda Y, Mizuta T, Fukada M, Nishigami T, Shimoyama T: Serum anti-Helicobacter pylori antibodies and gastritis. J Clin Gastroenterol 1995;21:S164–S168.
154.
Mitchell HM, Mascord K, Hazell SL, Daskalopoulos G: Association between the IgG subclass response, inflammation and disease status in Helicobacter pylori infection. Scand J Gastroenterol 2001;36:149–155.
155.
Suzuki H, Miura S, Imaeda H, Suzuki M, Han JY, Mori M, Fukumura D, Tsuchiya M, Ishii H: Enhanced levels of chemiluminescence and platelet activating factor in urease-positive gastric ulcer. Free Radic Biol Med 1996;20:449–454.
156.
Davies GR, Banatvala N, Collins CE, Sheaff MT, Abdi Y, Clements L, Rampton DS: Relationship between infective load of Helicobacter pylori and reactive oxygen metabolite production in antral mucosa. Scand J Gastroenterol 1994;29:419–424.
[PubMed]
157.
Danese S, Cremonini F, Armuzzi A, Candelli M, Papa A, Ojetti V, Pastorelli A, Di Caro S, Zannoni G, De Sole P, Gasbarrini G, Gasbarrini A: Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa. Scand J Gastroenterol 2001;36:247–250.
158.
Farinati F, Della Libera G, Cardin R, Molari A, Plebani M, Rugge M, Di Mario F, Naccarato R: Gastric antioxidant, nitrites, and mucosal lipoperoxidation in chronic gastritis and Helicobacter pylori infection. J Clin Gastroenterol 1996;22:275–281.
159.
Drake IM, Mapstone NP, Schorah CJ, White KL, Chalmers DM, Dixon MF, Axon AT: Reactive oxygen species activity and lipid peroxidation in Helicobacter pylori associated gastritis: relation to gastric mucosal ascorbic acid concentrations and effect of H. pylori eradication. Gut 1998;42:768–771.
[PubMed]
160.
Everett SM, Singh R, Leuratti C, White KL, Neville P, Greenwood D, Marnett LJ, Schorah CJ, Forman D, Shuker D, Axon AT: Levels of malondialdehyde-deoxyguanosine in the gastric mucosa: Relationship with lipid peroxidation, ascorbic acid, and Helicobacter pylori. Cancer Epidemiol Biomarkers Prev 2001;10:369–376.
[PubMed]
161.
Mizuki I, Shimoyama T, Fukuda S, Liu Q, Nakaji S, Munakata A: Association of gastric epithelial apoptosis with the ability of Helicobacter pylori to induce a neutrophil oxidative burst. J Med Microbiol 2000;49:521–524.
[PubMed]
162.
Kodama K, Sumii K, Kawano M, Kido T, Nojima K, Sumii M, Haruma K, Yoshihara M, Chayama K: Helicobacter pylori infection increases serum nitrate and nitrite more prominently than serum pepsinogens. Helicobacter 2002;7:9–13.
163.
Tari A, Kodama K, Kitadai Y, Ohta M, Sumii K, Kajiyama G: Is apoptosis in antral mucosa correlated with serum nitrite concentration in Japanese Helicobacter pylori-infected patients? J Gastroenterol Hepatol 2003;18:498–504.
164.
Shiotani A, Yanaoka K, Iguchi M, Saika A, Itoh H, Nishioka S: Helicobacter pylori infection reduces intraluminal nitric oxide in humans. Gastroenterology 1999;34:668–674.
165.
Li CQ, Pignatelli B, Ohshima H: Coexpression of interleukin-8 and inducible nitric oxide synthase in gastric mucosa infected with CagA+Helicobacter pylori. Dig Dis Sci 2000;45:55–62.
166.
Hahm KB, Lee KJ, Choi SY, Kim JH, Cho SW, Yim H, Park SJ, Chung MH: Possibility of chemoprevention by the eradication of Helicobacter pylori: oxidative DNA damage and apoptosis in H. pylori infection. Am J Gastroenterol 1997;92:1853–1857.
[PubMed]
167.
Antos D, Enders G, Rieder G, Stolte M, Bayerdorffer E, Hatz RA: Inducible nitric oxide synthase expression before and after eradication of Helicobacter pylori in different forms of gastritis. FEMS Immunol Med Microbiol 2001;30:127–131.
168.
Mannick EE, Bravo LE, Zarama G, Realpe JL, Zhang XJ, Ruiz B, Fontham ET, Mera R, Miller MJ, Correa P: Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacrter pylori gastritis: effect of antibiotics and antioxidants. Cancer Res 1996;56:3238–3243.
[PubMed]
169.
Verhulst ML, van Oijen AH, Roelofs HM, Peters WH, Jansen JB: Antral glutathione concentration and glutathione S-transferase activity in patients with and without Helicobacter pylori. Dig Dis Sci 2000;45:629–632.
170.
Shirin H, Pinto JT, Liu LU, Merzianu M, Sordillo EM, Moss SF: Helicobacter pylori decreases gastric mucosal glutathione. Cancer Lett 2001;164:127–133.
171.
Obst B, Wagner S, Sewing KF, Beil W: Helicobacter pylori causes DNA damage in gastric epithelial cells. Carcinogenesis 2000;21:1111–1115.
[PubMed]
172.
Kimura M, Goto S, Ihara Y, Wada A, Yahiro K, Niidome T, Aoyagi H, Hirayama T, Kondo T: Impairment of glutathione metabolism in human gastric epithelial cells treated with vacuolating cytotoxin from Helicobacter pylori. Microb Pathog 2001;31:29–36.
173.
Gotz JM, van Kan CI, Verspaget HW, Biemond I, Lamers CB, Veenendaal RA: Gastric mucosal superoxide dismutases in Helicobacter pylori infection. Gut 1996;38:502–506.
[PubMed]
174.
Noguchi K, Kato K, Moriya T, Suzuki T, Saito M, Kikuchi T, Yang J, Imatani A, Sekine H, Ohara S, Toyota T, Shimosegawa T, Sasano H: Analysis of cell damage in Helicobacter pylori-associated gastritis. Pathol Int 2002;52:110–118.
175.
Sobala GM, Schorah CJ, Shires S, Lynch DA, Gallacher B, Dixon MF, Axon AT: Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations. Gut 1993;34:1038–1041.
[PubMed]
176.
Banerjee S, Hawksby C, Miller S, Dahill S, Beattie AD, McColl KE: Effect of Helicobacter pylori and its eradication on gastric juice ascorbic acid. Gut 1994;35:317–322.
[PubMed]
177.
Mowat C, Carswell A, Wirz A, McColl KE: Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice. Gastroenterology 1999;116:813–822.
[PubMed]
178.
Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y: Endoscopic and histological comparison of non-ulcer dyspepsia with and without Helicobacter pylori infection evaluated by the modified Sydney system. Am J Gastroenterol 2000;95:2195–2199.
179.
Joshi A, Gupta SD, Ahuja V, Sharma MP: Symptom score does not correlate with gastritis grade and Helicobacter pylori infection in non-ulcer dyspepsia. Trop Gastroenterol 2001;22:194–196.
[PubMed]
180.
Luzza F, Maletta M, Imeneo M, Marcheggiano A, Biancone L, Pallone F: Mucosal and systemic antibody levels against Helicobacter pylori do not parallel gastric inflammatory changes. Ital J Gastroenterol Hepatol 1998;30:36–39.
[PubMed]
181.
Maaroos HI, Vorobjova T, Sipponen P, Tammur R, Uibo R, Wadstrom T, Keevallik R, Villako K: An 18-year follow-up study of chronic gastritis and Helicobacter pylori association of CagA positivity with development of atrophy and activity of gastritis. Scand J Gastroenterol 1999;34:864–869.
182.
Sande N, Nikulin M, Nilsson I, Wadstrom T, Laxen F, Harkonen M, Suovaniemi O, Sipponen P: Increased risk of developing atrophic gastritis in patients infected with CagA+Helicobacter pylori. Scand J Gastroenterol 2001;36:928–933.
183.
Vorobjova T, Ananieva O, Maaroos H, Sipponen P, Villako K, Utt M, Nilsson I, Wadstrom T, Uibo R: Seropositivity to Helicobacter pylori heat-shock protein 60 is strongly associated with intensity of chronic inflammation, particularly in antrum mucosa: an extension of an 18-year follow-up study of chronic gastritis in Saaremaa, Estonia. FEMS Immunol Med Microbiol 2001;30:143–149.
184.
Chang MC, Chang YT, Sun CT, Wu MS, Wang HP, Lin JT: Quantitative correlation of Helicobacter pylori stool antigen test with 13C-urea breath test by the updated Sydney grading system of gastritis. Hepatogastroenterology 2002;49:576–579.
[PubMed]
© 2005 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2005
You do not currently have access to this content.
